NIH PAR · NICHD · R01
PAR-25-265: Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for "high priority" genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a "high priority" condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and…
- NOFO number
- PAR-25-265
- Type
- PAR
- Activity code
- R01
- Primary institute
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Clinical trials
- Optional
- Posted
- Dec 2, 2024
- Opens
- Jan 5, 2025
- Expires
- Nov 17, 2027
PAR-25-265 due dates
3 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 05, 2025 | March 05, 2025 * | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 05, 2025 | July 05, 2025 * | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 05, 2025 | November 05, 2025 * | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 05, 2026 | March 05, 2026 * | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 05, 2026 | July 05, 2026 * | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 05, 2026 | November 05, 2026 * | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 05, 2027 | March 05, 2027 * | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 05, 2027 | July 05, 2027 * | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 05, 2027 | November 05, 2027 * | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-265
NIH RePORTER lists 2 projects funded under PAR-25-265 in FY2022–FY2026, with $909K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
1
Type 1 (new project) award records
NIH funding
$909K
Award dollars under PAR-25-265, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 1 | $909K |
Institutions with the most funding
- Icahn School of Medicine at Mount Sinai$726K · 1 project
- Yale University$183K · 1 project
Funding institutes
- NICHD$909K · 2
Activity codes funded
- R011 record
- R561 record
Most recent new awards
- Discovery of novel inhibitors of the AASS enzyme to treat glutaric aciduria type 1 through substrate reduction (opens NIH RePORTER)
Icahn School of Medicine at Mount Sinai · 1R01HD122293-01 · NICHD · Notice Aug 17, 2026
$726KR01
What its predecessor PAR-21-353 funded
PAR-25-265 reissues PAR-21-353. Its funding history is the best guide to who wins under this program: 6 projects and $10.7M in FY2022–FY2026.
Projects funded
6
Distinct projects, FY2022–FY2026
New awards
5
Type 1 (new project) award records
NIH funding
$10.7M
Award dollars under PAR-21-353, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 3 | 3 | $1.5M |
| FY2024 | 4 | 1 | $2.7M |
| FY2025 | 5 | 1 | $3.2M |
| FY2026 | 5 | 0 | $3.3M |
Institutions with the most funding
- Children's Hospital of Orange County$2.5M · 1 project
- Pacific Northwest Research Institute$2.4M · 1 project
- Seattle Children's Hospital$2.3M · 1 project
- Albert Einstein College of Medicine$2.2M · 1 project
- Washington University$1.3M · 1 project
- University of Missouri-Columbia$217K · 1 project
Funding institutes
- NICHD$10.7M · 17
Activity codes funded
- R0116 records
- R561 record
Most recent new awards
- Preclinical Testing of Early Life Anti-Myostatin Therapy for Osteogenesis (opens NIH RePORTER)
Washington University · 1R01HD119966-01 · NICHD · Notice Aug 14, 2025
$653KR01
- Development and application of variant interpretation platforms to advance detection of urea cycle disorders by newborn genome sequencing (opens NIH RePORTER)
Pacific Northwest Research Institute · 1R01HD114863-01 · NICHD · Notice Apr 23, 2024
$809KR01
- Preclinical testing of early life anti-myostatin therapy for osteogenesis imperfecta (opens NIH RePORTER)
University of Missouri-Columbia · 1R56HD110848-01 · NICHD · Notice Jul 27, 2023
$217KR56
- Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I (opens NIH RePORTER)
Children's Hospital of Orange County · 1R01HD106916-01A1 · NICHD · Notice May 5, 2023
$709KR01
- Development of a Multiplex Proteomics Assay for High-Throughput Newborn Screening of a New Set of Treatable Neonatal Diseases (opens NIH RePORTER)
Seattle Children's Hospital · 1R01HD111410-01 · NICHD · Notice Apr 18, 2023
$583KR01
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-265. Contact the program officer at the institute that fits your research before applying.
- NICHD · Eunice Kennedy Shriver National Institute of Child Health and Human Development
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Award terms
- Application types allowed
- NewRenewalResubmissionRevision The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are not limited but need to reflect the actual needs of the proposed project.
- Project period
- The scope of the proposed project should determine the project period. The maximum project period is 5 years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-21-353.
- Companion NOFOs: PAR-25-266.
Other open NOFOs for R01
- PAR-25-362Early Immune System Development and Ontogeny (R01 Clinical Trial Optional)NICHD · next due Feb 5, 2027
- PAR-25-112Advancement and Innovation in Measurement of Language Development and Predictors (R01 Clinical Trial Not Allowed)NICHD · next due Feb 5, 2027
- PAR-25-227Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional)NICHD · next due Feb 5, 2027
- PAR-25-185Screening and Functional Validation of Genomic Variants Associated with Human Congenital Anomalies (R01 Clinical Trial Not Allowed)NICHD · next due Feb 5, 2027
- PAR-25-371Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)NHGRI · next due Oct 20, 2026
- PAR-25-379Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)NIDA · next due Oct 21, 2026
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.